Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
11
05
2020
accepted:
12
05
2020
pubmed:
20
5
2020
medline:
29
7
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.
Identifiants
pubmed: 32425638
doi: 10.1016/j.ijid.2020.05.040
pii: S1201-9712(20)30347-7
pmc: PMC7231497
pii:
doi:
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
431-439Subventions
Organisme : Medical Research Council
ID : MR/M009149/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
Crit Care Med. 2020 May;48(5):e391-e399
pubmed: 32187077
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Lancet Respir Med. 2019 Feb;7(2):154-162
pubmed: 30455077
NPJ Regen Med. 2019 Dec 2;4:22
pubmed: 31815001
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Adv Exp Med Biol. 2017;972:49-60
pubmed: 27966107
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Arthritis Res Ther. 2015 Mar 31;17:88
pubmed: 25880839
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
EClinicalMedicine. 2020 Jan 17;19:100249
pubmed: 31989101
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Feb 22;395(10224):e35-e36
pubmed: 32035018
Stem Cells. 2018 Apr;36(4):602-615
pubmed: 29341339
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Lancet. 2020 Mar 28;395(10229):1063-1077
pubmed: 32145185
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Respir Res. 2014 Apr 04;15:39
pubmed: 24708472
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Int J Infect Dis. 2015 Nov;40:71-4
pubmed: 26365771
Infect Dis Clin North Am. 2019 Dec;33(4):869-889
pubmed: 31668196
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Stem Cells Int. 2018 Jun 14;2018:3057624
pubmed: 30013600
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Stem Cells Transl Med. 2019 Nov;8(11):1126-1134
pubmed: 31282113
Stem Cells Dev. 2015 Mar 15;24(6):677-85
pubmed: 25517941
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
J Bone Joint Surg Am. 2019 May 15;101(10):904-911
pubmed: 31094982
Cytotherapy. 2016 Sep;18(9):1197-208
pubmed: 27424149
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
Lancet Oncol. 2020 Feb;21(2):205-206
pubmed: 32007195
Lancet Respir Med. 2014 Dec;2(12):1016-26
pubmed: 25465643
Front Cell Dev Biol. 2020 Jan 23;7:362
pubmed: 32039196
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Nat Rev Immunol. 2012 Apr 25;12(5):383-96
pubmed: 22531326
Front Immunol. 2019 Jun 04;10:1191
pubmed: 31214172
Front Immunol. 2017 Nov 24;8:1626
pubmed: 29225601
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
Front Immunol. 2020 Feb 18;11:243
pubmed: 32133010